Stem Cell Index: YTD Analysis, Banking on NeoStem

biotechThe ETF Innovators Global Stem Cell and Regenerative Medicine Index tracks the performance of 40 stem cell and regenerative medicine companies on a global basis with market caps of less than $1 billion at the inception of the index. The total market value of the index will be tracked as a gauge of investor and trader sentiment toward stem cell companies from a starting value of 3,928 on 2/22/09.

The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which is down 10% at a composite market value of 3,533 from 3,928 at the index inception on 2/22/09. The index is down by 23.7% over the past year on an equal-weight basis, compared to losses of 24.5% for the Healthcare Sector SPDR (XLV), 16.2% for iShares Nasdaq Biotech (IBB), 18.5% for SPDR S&P Biotech (XBI), 28.5% for PowerShares Biotech & Genome (PBE), and 36.9% for the S&P 500 SPDR (SPY).

On a year-to-date basis (YTD), the stem cell index is up 28.8% on an equal-weight basis, thanks to major gains in many of the smallest companies in the index with the companies listed in the table in descending order by their YTD stock price changes. The stem cell index performance on a YTD basis compares favorably to losses of 9.1% for the Healthcare Sector SPDR (XLV), 6.8% for iShares Nasdaq Biotech (IBB), 13.5% for SPDR S&P Biotech (XBI), 6.6% for PowerShares Biotech & Genome (PBE), and 4.9% for the S&P 500 SPDR (SPY).

Integra LifeSciences (IART) regained its position as the market cap leader in the index at $634M since I last wrote about the index one month ago. Osiris Therapeutics (OSIR) has lost over one-third of its market value so far this year after halting a Phase 3 clinical trial in late March for what the Company termed a flawed trial design resulting in higher than expected placebo response rates. The most widely followed and traded proxy included in the index is StemCells (STEM), which has gained about 15% YTD and 8% over the past year.

One of the top 10 stock price gainers YTD (registering a gain of nearly 100%) is NeoStem (NBS), which is a leader in the pre-disease collection, processing and long-term storage of adult stem cells for future medical applications. Click here for a link to NeoStem’s five minute adult stem cell documentary video, which is hosted at their website.

Full Story:

Leave a Reply

Your email address will not be published. Required fields are marked *